MetLife, Inc. (MET), one of the world's largest life insurers and a major provider of employee benefits, annuities, and asset management, has climbed toward multi-year highs in 2026. The stock recently traded near $100, and a cluster of fresh analyst price targets now points toward $110 or higher. That raises a straightforward question for investors: can MET reach $110?
MetLife enjoys broad but not unanimous Street support. Roughly a dozen current targets, mostly dated between August and October 2026, sit in a $106 to $119 band. Recent examples include Bank of America at $119, TD Cowen at $114 (raised from $110), Barclays at $111, Morgan Stanley at $111, and a large group—J.P. Morgan, Wells Fargo, Piper Sandler, and UBS—clustered at $110. Keefe, Bruyette & Woods is at $108, Mizuho at $109, and Evercore ISI at $106.
The arithmetic mean of these above-price targets is roughly $111, which rounds to a clean $110 central target. Because a few more cautious, lower targets (as low as about $84) drag the full-consensus average down to the mid-$100s—only high single digits above the current price—this analysis uses the average of the targets above the current price, as required to keep a meaningful upside gap. The resulting ~10% gap is real but hardly a runaway forecast.
The reasoning behind the bullish targets is consistent: MetLife's investment income benefits from relatively higher interest rates, its group benefits and retirement income businesses are growing, and share buybacks plus a growing dividend support per-share value. Cautious analysts, by contrast, flag interest-rate sensitivity and the insurer's commercial real estate book.
MET recently closed near $100, leaving a required move of roughly 10% to reach $110. For a large, mature insurer, a 10% advance is a modest-to-moderate move—meaningful, but not the kind of re-rating that would require a dramatic earnings surprise. MetLife has already traveled a long way: its 52-week range spans roughly $67 to $101, so the stock is trading near the top of that band as it approaches the $110 objective.
The path would likely run through continued delivery on earnings and guidance. Analysts model EPS (earnings per share) of roughly $10.22 for 2026, up mid-teens from the prior year, with further growth toward roughly $11.16 the following year. Q2 2026 results beat expectations, and the next quarterly report is scheduled for early November 2026, giving investors a near-term checkpoint.
Technically, MET sits just below a meaningful area: the $100 round-number level and the 52-week high near $101 act as near-term resistance. Clearing and holding above that zone would open the path toward the $110 objective. On the downside, the prior consolidation in the low-to-mid $90s—an area through which the stock climbed during 2026—represents the first notable support zone, with the broader uptrend still intact above it.
Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms differ, and no single timeline is guaranteed. The most important near-term catalyst is MetLife's quarterly earnings and guidance, due in early November 2026. Investors should also watch analyst revisions, interest-rate decisions from the Federal Reserve, credit conditions in commercial real estate, and any changes to buyback or dividend policy.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from shifting market conditions, technical behavior, and AI-driven analysis. The tool is designed to help traders discover opportunities, track positions, and spot changing trends more efficiently than manual review allows. For those following MET or the broader insurance sector, it offers a data-driven way to stay ahead of turning points.
A move to $110 would require MetLife to advance roughly 10% from its recent level near $100—a moderate step for a company whose earnings, investment income, and capital returns are trending higher and whose analyst targets have been rising in tandem. The supporting case rests on higher-for-longer interest rates, group benefits growth, buybacks, and a valuation discount. The principal obstacles are rate cuts, commercial real estate credit, and the fact that much of 2026's re-rating may already be reflected near the 52-week high. With analyst targets split between a confident $106–$119 cluster and a cautious sub-$100 minority, the $110 level is a reasonable focal point for discussion—but not a guarantee.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, MET has been closely correlated with PRU. These tickers have moved in lockstep 72% of the time. This A.I.-generated data suggests there is a high statistical probability that if MET jumps, then PRU could also see price increases.